It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying ...

Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why I rate DERM stock a Buy.

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other safe stocks to ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Gorman sold 146,105 ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...

Ultragenyx Pharmaceutical is a mid-cap biotech firm with a promising pipeline and an optimistic outlook from analysts. Click ...

Jefferies analyst Akash Tewari adjusted the price target for Zentalis Pharmaceuticals (NASDAQ:ZNTL), bringing it down to $2.50 from the previous figure of $6.00, while reiterating a Hold rating on the ...